Why does a little pause make a big impact?

How do you keep showing up when the hundredth investor says no?

And what does it mean to be a CEO when there’s no team yet – and every job title belongs to you?

Today we’re speaking with Mihriban Tuna, CEO of Immutrin based in Cambridge UK, a company developing best-in-class antibody-based therapy for depleting cardiac amyloid in ATTR amyloidosis.

We’ll talk more about the science at the end of the episode.

About LifeScience ORG

It’s no secret that Europe is a global leader in generating translational science. We’re grateful at LifeScience ORG to have a community of over 400 life science CEOs – leaders driving change in biotech, medtech, techBio and healthcare.

The conversations inside our community – stories of conviction, navigating challenges, and making bold decisions – inspire us every week. To hear the stories, lessons, and experiences of our life science leaders, listen to A Call to Lead @ LifeScience ORG, available on all good podcasting platforms.

Chapters

1:08 - From Scientist to CEO

3:48 - Learning Through Failure

5:58 - The Call to Step Up

9:40 - Leading Through Crisis

12:03 - The Fundraising Crucible

19:13 - Building the Right Team

23:50 - Keeping Perspective Under Pressure

30:18 - Tackling Cardiac Amyloidosis

37:18 - The Unsung Heroes of Leadership